Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -6 of 6 Show results per page	View Search Criteria \| Help With Results

Last Modified: 4/24/2003 First Published: 8/1/2001


1.		Phase III Study of Epratuzumab in Patients With Rituximab-Refractory Low-Grade Follicular B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0009041 IM-T-hLL2-07, UCLA-BB-IND-7124, NCI-G01-2004, NCT00022685

Last Modified: 3/1/1999 First Published: 1/1/1998


2.		Phase I/II Study of Immunotherapy with Humanized Monoclonal Antibody LL2 in Patients with Recurrent Non-Hodgkin's Lymphoma (Summary Last Modified 03/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Not specified				Pharmaceutical / Industry				UNMC-289-97 IM-h-LL2-01, NCI-V97-1353

Last Modified: 9/10/2003 First Published: 8/1/2002


3.		Phase II Randomized Study of Epratuzumab in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0201056 AMGEN-AMG-412-159, NCI-G02-2094, NCT00042913

Last Modified: 2/27/2003 First Published: 1/26/2003


4.		Phase II Study of Epratuzumab and Rituximab in Patients With Refractory or Recurrent Low-Grade CD20-Positive B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0109058 AMGEN-20010138, NCT00054379

Last Modified: 8/16/2007 First Published: 3/3/2006


5.		Phase II Study of Epratuzumab and Rituximab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (CHOP) in Patients With Previously Untreated Stage II, III, or IV Diffuse Large B-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				NCCTG-N0489 N0489, NCT00301821

Last Modified: 6/1/1995


6.		Phase I Pilot Study of 131I-Labeled MOAB LL2 for B-Cell non-Hodgkin's Lymphoma (Summary Last Modified 06/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				over 18								UCHSC-91264 NCI-V91-0216

Select All on One Page